Biogen

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

28.94B

Market cap28.94B

Price-Earnings ratio

20.26

Price-Earnings ratio20.26

Dividend yield

—

Dividend yield—

Average volume

1.04M

Average volume1.04M

High today

$196.36

High today$196.36

Low today

$187.48

Low today$187.48

Open price

$187.69

Open price$187.69

Volume

891.30K

Volume891.30K

52 Week high

$205.97

52 Week high$205.97

52 Week low

$121.05

52 Week low$121.05

Stock Snapshot

As of today, Biogen(BIIB) shares are valued at $195.96. The company's market cap stands at 28.94B, with a P/E ratio of 20.26.

As of 2026-06-04, Biogen(BIIB) stock has fluctuated between $187.48 and $196.36. The current price stands at $195.96, placing the stock +4.5% above today's low and -0.2% off the high.

The Biogen(BIIB)'s current trading volume is 891.3K, compared to an average daily volume of 1.04M.

During the past year, Biogen(BIIB) stock moved between $121.05 at its lowest and $205.97 at its peak.

BIIB News

Simply Wall St 4h

Mixed Lupus Win And Parkinson’s Setback Might Change The Case For Investing In Biogen

In May 2026, Biogen’s partner UCB reported positive Phase 3 PHOENYCS GO results for dapirolizumab pegol in moderate-to-severe active systemic lupus erythematosu...

Simply Wall St 5d

A Look At Biogen Valuation After Earnings Beat And Parkinson’s Setback

Biogen (BIIB) is in focus after two headline events: a first quarter 2026 earnings beat with steady revenue guidance but lower earnings expectations, and the di...

TipRanks 6d

Biogen and Denali’s BIIB122 Parkinson’s Trial Completion Sets Up Key Catalyst for Investors

Denali Therapeutics (DNLI), Biogen Inc. (BIIB) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks P...

Analyst ratings

55%

of 38 ratings

Buy

55.3%

Hold

39.5%

Sell

5.3%

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.